Alnylam Inks $2B AI Pact With Inceptive to Speed RNA Discovery

Daily Biopharma Digest — June 4, 2026

• Alnylam Pharmaceuticals struck a $2 billion AI collaboration with Inceptive to accelerate RNA drug discovery.
• Eli Lilly’s $1.9 billion genetic medicine partnership with Ascidian (continued coverage from June 3).
• ADC Therapeutics faces serious safety questions after Zynlonta showed three times as many deaths in a clinical trial’s treatment arm versus control.
• Autobahn Therapeutics reported successful Phase 2 data in bipolar depression, setting up a pivotal trial.

What to Watch

• Zynlonta Regulatory Fallout — FDA’s response to the threefold mortality signal in ADC Therapeutics’ trial could set precedent for how accelerated approvals are reassessed when confirmatory trials reveal safety concerns.
• AI-Driven Drug Discovery ROI — With Alnylam’s $2B Inceptive deal and similar partnerships proliferating, the industry will soon face scrutiny on whether AI collaborations deliver measurable productivity gains versus traditional discovery.
• Bipolar Depression Pipeline — Autobahn’s positive Phase 2 data with a novel thyroid receptor mechanism could catalyze renewed interest in a therapeutic area that has seen limited innovation despite high unmet need.
• European Pharma Investment Climate — Lilly’s German manufacturing pullback may foreshadow broader capital flight from Europe if cost-cutting policies continue, potentially shifting manufacturing hubs to Asia or the U.S.